个性化文献订阅>期刊> Biochemical and Biophysical Research Communications
 

Longistatin, a novel plasminogen activator from vector ticks, is resistant to plasminogen activator inhibitor-1

  作者 Anisuzzaman; Islam, MK; Alim, MA; Miyoshi, T; Hatta, T; Yamaji, K; Matsumoto, Y; Fujisaki, K; Tsuji, N  
  选自 期刊  Biochemical and Biophysical Research Communications;  卷期  2011年413-4;  页码  599-604  
  关联知识点  
 

[摘要]Thrombo-occlusive diseases are major causes of morbidity and mortality, and tissue-type plasminogen activator (t-PA) is recommended for the treatment of the maladies. However, both t-PA and u-PA are rapidly inactivated by plasminogen activator inhibitor-1 (PAI-1). Here, we show that longistatin, a novel plasminogen activator isolated from the ixodid tick, Haemaphysalis longicornis is resistant to PAI-1. Longistatin was relatively less susceptible to the inhibitory effect of SDS-treated platelet lysate than physiologic PAs. Platelet lysate inhibited t-PA and tcu-PA with the IC(50) of 7.7 and 9.1 mu g/ml, respectively, whereas for longistatin inhibition IC(50) was 20.1 mu g/ml (p < 0.01). Similarly, activated PAI-1 (20 nM) inhibited only 21.47% activity of longistatin but almost completely inhibited t-PA (99.17%) and tcu-PA (96.84%). Interestingly, longistatin retained 76.73% initial activity even after 3 h of incubation with 20 nM of PAI-1. IC(50) of PAI-1 during longistatin inhibition was 88.3 nM while it was 3.9 and 3.2 nM in t-PA and tcu-PA inhibition, respectively. Longistatin completely hydrolyzed fibrin clot by activating plasminogen efficiently in the presence of 20 nM of PAI-1. Importantly, unlike t-PA, longistatin did not form complex with PAI-1. Collectively, our results suggest that longistatin is resistant to PAI-1 and maybe an interesting tool for the development of a PAI-1 resistant effective thrombolytic agent. (C) 2011 Elsevier Inc. All rights reserved.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内